期刊文献+

结直肠癌肝转移与门静脉血K-ras基因突变的关系 被引量:2

Relationship between K-ras oncogene mutations in portal vein blood of patients with colorectal cancer and liver metastases
原文传递
导出
摘要 目的 检测结直肠癌患者门静脉血液、原发癌组织及肝转移灶中K-ras基因突变,探讨K-ras突变与结直肠癌肝转移的关系.方法 采用实时荧光定量聚合酶链反应(PCR)技术和基因测序技术检测48例结直肠癌患者门静脉血液、原发肿瘤组织、相应的癌旁肠黏膜以及8例肝转移灶组织中K-ras基因突变.结果 48例结直肠癌组织中17例(35.4%)发现K-ras基因突变,48例癌旁黏膜中4例(8.3%)发现K-ras基因突变,明显低于癌组织的基因突变率(P<0.05).48例结直肠癌患者中16例(33.3%)门静脉血中发现K-ras基因突变,与癌组织的基因突变率差异无统计学意义(P>0.05).有肝转移患者门静脉血中K-ras基因突变率(7/10,70.0%)明显高于无肝转移者(9/38,23.7%,P<0.05).16例门静脉血存在K-ras基因突变者,其相应的肿瘤组织中均发现K-ras突变.而结直肠癌组织中无K-ras基因突变者,患者门静脉血及癌旁黏膜无基因突变.8例同时性肝转移患者中5例门静脉血发现K-ras基因突变,且其相应的肝转移灶组织也发现相同的K-ras突变.2例异时性肝转移患者门静脉血检测到K-ras基因突变,手术时无肝转移,但分别于术后第6个月和第9个月经CT检查证实有肝转移.原发肿瘤组织K-ras基因突变类型与门静脉血、肝脏转移灶的K-ras基因突变一致,即K-ras基因12密码子GGT突变为GAT或GTT.结论 结直肠原发癌组织和患者门静脉血有K-ras基因的突变,预示着肿瘤可能有肝脏转移. Objective To detect mutations of K-ras oncogene in portal vein blood of patients with colorectal cancer, and to find out the relationship between mutated K-ras oncogene and liver metastases in colorectal cancer. Methods Forty-eight patients with colorectal cancer were screened for the mutations of K-ras oncogene in tissue samples from their tumors, portal vein blood, proximally adjacent mucosa and 8metastatic liver biopsies by real-time fluorescence quantitative polymerase chain reaction (PCR) and DNA sequencing. The results were analyzed with their clinical data. Results Sixteen of the 48 patients with colorectal cancer had K-ras point mutations at codon 12 in their portal vein blood, and 17 of 48 patients had K-ras mutations in their primary tumors, but only 4 of 48 patients had K-ras mutations in proximally adjacent mucosa. There was no significant difference in rate of K-ras mutation between tumor tissues and portal vein blood (P 〉 0. 05 ), but significant difference was found between the tumor tissue and the proximally adjacent mucosa ( P 〈0. 05 ). The rate of K-ras mutations in portal vein blood of colorectal cancer with liver metastases (70. 0% ) was higher than that of without liver metastases (23.7%). Sixteen cases of mutated K-ras in portal vein blood showed mutations in tumor tissues. Patients without mutated K-ras in tumor tissue had no mutations in their portal vein blood and proximally adjacent mucosa. In 5 of 8 patients with simultaneous liver metastasis, mutated K-ras oncogenes were detected in portal vein blood, and the type of K-ras mutation detected in the tumor tissue was accord with that in metastatic liver biopsies. Two patients with mutated K-ras detected in their portal vein blood had no liver metastases during perioperation, but liver metastases were diagnosed by CT at the postoperative month 6 and 9 respectively. The main types of K-ras mutations at codon 12 included GGT to GAT and GGT to GTT. No one had point mutation at codon 13. Conclusion Mutated K-ras detected in both cancer tissue and portal vein blood may indicate livermetastases from colorectal cancer.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2011年第2期248-251,共4页 Chinese Journal of Experimental Surgery
基金 广州市黄埔区科技计划项目(2009031)
关键词 结直肠肿瘤 K—ras基因 突变 肝转移 Colorectal neoplasms Ras gene Mutation Hepatic metastasis
  • 相关文献

参考文献9

二级参考文献18

  • 1崔明,刘武红,杨彦,徐辉.联合检测大肠癌患者外周血CK20 mRNA和CEA mRNA的临床意义[J].中华实验外科杂志,2004,21(5):615-616. 被引量:7
  • 2高枫,唐卫中,李卫.中国人散发性大肠癌K-ras基因突变的研究[J].中华实验外科杂志,2005,22(1):65-67. 被引量:22
  • 3郁宝铭.胃肠道肿瘤分子生物学研究的发展方向[J].中华实验外科杂志,2005,22(10):1162-1163. 被引量:10
  • 4周立生,李大鹏,王斌,李继坤.结直肠癌术后肝转移相关因素分析[J].中国癌症杂志,2006,16(5):394-395. 被引量:6
  • 5Weber SM,Jamagin WR, DeMatteo RP, et al. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol, 2000,7: 643-650.
  • 6Doolittle BR, Emannel J, Turtle C, et al. Detection of the mutated K- ras biomarker in colorectal carcinoma. Exp Mol Pathol, 2001,70: 289-301.
  • 7Fearon ER, Vogelstein BA. A genetic model for colorectal tumorigenesis. Cell. 1990.61:759-767.
  • 8Wei Li, Gao Feng, Junlin Liang, et al. Estimation of the optiomal electrophorectic temperature of DNA single strand conformation by DNA base composition. Electrophoresis, 2003,14 : 2283-2289.
  • 9Fischer SG, Lerman LS. DNA fragment differing by single base-pair substitutions are separated in denaturing gradient gels: correspondence with melting theory. Proc Natl Acad Sci, 1983, 80 : 1579-1582.
  • 10Barbacld M, Saito H, Clement JM, et al. Ras gene. Ann Rev Biochem,1987, 56: 781-827.

共引文献37

同被引文献19

  • 1万德森.结直肠癌肝转移治疗的进展[J].癌症,1997,16(1):1-4. 被引量:23
  • 2Metzger B,Chambeau L,Begon DY,et al. The human epidemml growth factor receptor (EGFR) gene in European patients with advanced color- ectal cancer harbors infrequent mutations in its tyrosine kinase domain. BMC Med Genet ,2011,12 : 144.
  • 3Stintzing S, Fischer von Weikersthal L, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of pa- tients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol,2012,23 : 1693-1699.
  • 4Bihl MP, Hoeller S,Andreozzi MC,et al. KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons GI2 and G13. Diagn Mol Pathol, 2012,21:14-23.
  • 5Modest DP, Reinacher-Schick A, Stintzing S, et al. Cetuximab-bascd or bevacizumab-based first-line treatment in patients with KRAS p. Gl3D-mutated metastatic colorectal cancer: a pooled analysis. Anti- cancer Drugs,2012,23:666-673.
  • 6Rojas AM,Fuentes G,Rausall A,et at. The Ras protein superfamily: evolutionary tree and role of conserved amino acids. J Cell Bio1,2012, 196 : 189-201.
  • 7Merrell MA,Wakchoure S, Lehenkari PP, et at. Inhibition of the me- valonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. Eur J Pharmaco1,2007,570:27-37.
  • 8Oades GM, Senaratne SG, Clarke IA, et at. Nitrogen containing bi- sphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer ceils. J Urol, 2003,170:246-252.
  • 9Sewing L, Steinberg F, Schmidt H, et at. ,The bisphosphonate zoledron- ic acid inhibits the growth of HCT-116 colon carcinoma cells and in- duces tumor cell apoptosis. Apoptosis,2008,13:782-789.
  • 10Monkkonen H, Kuokkanen J, Holen I, et at. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Antieancer Drugs ,2008,19:391-399.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部